Portal de Periódicos da CAPES

Lung Cancer Wherein Durvalumab Induced Both Anti-CRMP-5 Antibody-related Paraneoplastic Neurological Syndromes and Neurological Adverse Events

2023; The Japanese Society of Internal Medicine; Volume: 63; Issue: 7 Linguagem: Inglês

10.2169/internalmedicine.1771-23

1349-7235

Tomokazu Seki, Kousuke Baba, Tomohiro Hayashi, Risako Furuta, Hiroaki Hirosawa, Taichi Mitsui, Hiroki Maesaka, Syuhei Takasawa, Toshiro Miwa, Keiko Tanaka, Yuji Nakatsuji,

Melanoma and MAPK Pathways

A 68-year-old man with small-cell lung cancer developed anti-collapsin response-mediator protein (CRMP)-5 antibody-related paraneoplastic neurological syndrome (PNS) presenting with ataxia and chorea during treatment with durvalumab. As a result of steroid therapy, anti-CRMP-5 antibodies became negative, hyperintense lesions on brain magnetic resonance imaging disappeared, and neurological symptoms improved. After resuming durvalumab, he became unable to walk due to neurological adverse events (nAEs). There have been no reported cases manifesting PNSs and nAEs as a result of the same immune checkpoint inhibitors (ICIs) administered at different times. Resuming ICIs in patients diagnosed with PNSs should be performed with prudence. (98/100)